Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
LNSRthis companyLENSAR Inc	$5.62	-4.05×	-5.34×	2.38×	-4.33×	-927.5%	46.4%	-42.1%	-58.7%	131.7%	-77.8%	-10.7%	-0.11×	0.34×	0×	1.15×	0.0%	5	0.85	4	A-
ANIKAnika Therapeutics, Inc.	$14.53	-12.64×	0.96×	1.22×	-29.78×	-96.9%	56.6%	-9.8%	-9.6%	-7.6%	-6.5%	3.2%	0.18×	8.73×	0×	4.72×	0.0%	5	4.93	2	B-
ARAYAccuray Incorporated	$3.97	-0.64×	0.76×	0.08×	-27.22×	-794.6%	27.7%	-6.6%	-12.2%	-118.0%	-10.1%	-40.6%	4.41×	-22.28×	-0.75×	1.5×	0.0%	2	-0.71	2	C
AVRAnteris Technologies Global Corp.	$5.98	-1.96×	-1,980.52×	96.28×	-1.88×	-109.8%	-16.6%	-4908.2%	-4921.3%	101230.1%	-4256.3%	-43.3%	-24.54×	0.11×	-1,286.22×	0.73×	0.0%	3	13.88	2	C
CRBPCorbus Pharmaceuticals Holdings, Inc.	$3.51	-1.38×	0.73×	0×	-1.04×	-49.7%	0.0%	0.0%	0.0%	-53.2%	-57.2%	-59.5%	0.01×	0.34×	0×	8.07×	0.0%	1	-6.62	2	B-
CRDFCardiff Oncology, Inc.	$0.84	-4.07×	4.14×	316.73×	-3.81×	-96.7%	100.0%	-8256.3%	-7732.0%	-101.0%	-105.9%	-20.2%	0.02×	0.37×	0×	3.67×	0.0%	2	-16.02	2	C
Peer median	—	-1.96×	0.76×	1.22×	-3.81×	-96.9%	27.7%	-9.8%	-12.2%	-53.2%	-57.2%	-40.6%	0.02×	0.34×	0×	3.67×	0.0%	2	-0.71	2	—